{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:43:00Z","timestamp":1788273780135,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AIRC (Italian Association for Cancer Research) IG 2019 grant","award":["23001"],"award-info":[{"award-number":["23001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Systemic mastocytosis (SM) is due to the pathologic accumulation of neoplastic mast cells in one or more extracutaneous organ(s). Although midostaurin, a multikinase inhibitor active against both wild-type and D816V-mutated KIT, improves organ damage and symptoms, a proportion of patients relapse or have resistant disease. It is well known that Aurora kinase A (AKA) over-expression promotes tumorigenesis, but its role in the pathogenesis of systemic mastocytosis (SM) has not yet been investigated. Evidence from the literature suggests that AKA may confer cancer cell chemo-resistance, inhibit p53, and enhance Polo-like kinase 1 (Plk1), CDK1, and cyclin B1 to promote cell cycle progression. In this study, we aimed to investigate the pathogenetic role of AKA and Plk1 in the advanced forms of SM. We demonstrate here, for the first time, that SM cell lines display hyper-phosphorylated AKA and Plk1. Danusertib (Aurora kinase inhibitor) and volasertib (Plk1 inhibitor) inhibited growth and induced apoptotic cell death in HMC-1.1 and -1.2 cells. Their growth-inhibitory effects were associated with cell cycle arrest and the activation of apoptosis. Cell cycle arrest was associated with increased levels of phospho-Wee1. Wee1 inhibition by MK1775 after 24 h treatment with danusertib or volasertib, when cells were arrested in G2 phase and Wee1, was overexpressed and hyper-activated, resulting in a significantly higher rate of apoptosis than that obtained from concomitant treatment with danusertib or volasertib + MK1775 for 48 h. In conclusion, Plk1 and AKA, alone or together with Wee1, are attractive therapeutic targets in neoplastic MCs. Repurposing Plk1 or AKA \u00b1 Wee1 inhibitors in advanced clinical development for other indications is a therapeutic strategy worthy of being explored, in order to improve the outcome of patients with advanced SM.<\/jats:p>","DOI":"10.3390\/cancers14030738","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T08:20:29Z","timestamp":1643617229000},"page":"738","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells"],"prefix":"10.3390","volume":"14","author":[{"given":"Manuela","family":"Mancini","sequence":"first","affiliation":[{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Monaldi","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Santis","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Rondoni","sequence":"additional","affiliation":[{"name":"Ospedale Santa Maria delle Croci, 48121 Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-5691","authenticated-orcid":false,"given":"Chiara","family":"Sartor","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Curti","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-0595","authenticated-orcid":false,"given":"Samantha","family":"Bruno","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"ref_1","first-page":"385","article-title":"Biology, classification and treatment of human mastocytosis","volume":"108","author":"Valent","year":"1996","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"Horny","year":"2001","journal-title":"Leuk Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: Current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: State of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu. Rev. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"ref_7","first-page":"e18385","article-title":"The Role of Avapritinib for the Treatment of Systemic Mastocytosis","volume":"13","author":"Sumbly","year":"2021","journal-title":"Cureus"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sammarco, G., Gallo, G., Vescio, G., Picciariello, A., De Paola, G., Trompetto, M., Curr\u00f2, G., and Ammendola, M. (2020). Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forth-coming Era of Precision Medicine. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092852"},{"key":"ref_9","first-page":"315","article-title":"Role of mast cells in tumor growth","volume":"37","author":"Conti","year":"2007","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_10","first-page":"8910","article-title":"Possible bio-logical and translational significance of mast cells density in colorectal cancer","volume":"20","author":"Marech","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/jcmm.12073","article-title":"High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression","volume":"17","author":"Malfettone","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/1078-0432.CCR-09-1380","article-title":"Targeting polo-like kinase in cancer therapy","volume":"16","author":"Degenhardt","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrc2964","article-title":"Shared and separate functions of polo-like kinases and aurora kinases in cancer","volume":"10","author":"Lens","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1841","article-title":"Targeting polo-like kinase 1 for cancer therapy","volume":"6","author":"Strebhardt","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1634\/theoncologist.2009-0010","article-title":"Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology","volume":"14","year":"2009","journal-title":"Oncologist"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4161\/cc.5.8.2692","article-title":"Polo-like kinases: A team in control of the division","volume":"5","author":"Medema","year":"2006","journal-title":"Cell Cycle"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1006\/bbrc.1997.7378","article-title":"On the regulation and function of human polo-like kinase 1 (PLK1): Effects of overexpression on cell cycle progression","volume":"239","author":"Mundt","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0962-8924(00)01880-8","article-title":"Chromosomal passengers and the (aurora) ABCs of mitosis","volume":"11","author":"Adams","year":"2001","journal-title":"Trends Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","article-title":"The cellular geography of aurora kinases","volume":"4","author":"Carmena","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35048096","article-title":"Mitotic kinases as regulators of cell division and its checkpoints","volume":"2","author":"Nigg","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2018-99-113278","article-title":"MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment","volume":"132","author":"Mancini","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/leu.2017.183","article-title":"SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis","volume":"32","author":"Martinelli","year":"2018","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"ref_24","first-page":"181","article-title":"Mastocytosis","volume":"34","author":"Carter","year":"2014","journal-title":"Allergy Clin. N. Am."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemicmastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J. Pathol."},{"key":"ref_28","first-page":"589","article-title":"Targeting Aurora-2 kinase in cancer","volume":"2","author":"Warner","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3324\/haematol.2010.031328","article-title":"Polo-like kinase-1 as a novel target in neoplastic mast cells: Demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536","volume":"96","author":"Peter","year":"2011","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12929-015-0150-2","article-title":"Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family","volume":"22","author":"Kawai","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000444942","article-title":"Mast Cell-Targeted Strategies in Cancer Therapy","volume":"43","author":"Ammendola","year":"2016","journal-title":"Transfus. Med. Hemotherapy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3324\/haematol.2018.195867","article-title":"Preclinical human models and emerging therapeutics for advanced systemic mastocytosis","volume":"103","author":"Arock","year":"2018","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Leo, E., Mancini, M., Aluigi, M., Luatti, S., Castagnetti, F., Testoni, N., Soverini, S., Santucci, M.A., and Martinelli, G. (2013). BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081425"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.cellsig.2014.04.010","article-title":"A calpain-cleaved fragment of \u03b2-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib","volume":"26","author":"Mancini","year":"2014","journal-title":"Cell. Signal."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/738\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:11:48Z","timestamp":1760134308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030738"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030738","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]}}}